Chugai Pharma UK - About Us

  • 1925 Founded
    • Juzo Ueno founded Chugai Shinyaku Co., Ltd. and began the import and sale of medicinal drugs (March 1925)
  • Commenced drug manufacturing (1927)
  • 1943 Incorporated
  • Acquired Matsunaga Pharmaceutical Co., Ltd. (1944)
  • Constructed the Kagamiishi Plant (1946)
  • Stock listed on the Tokyo Stock Exchange, Inc. (1956)
  • Constructed the Ukima Plant, Tokyo. (1957)
  • Constructed a general research laboratory
    (Takada Research Laboratory, Tokyo) (1960)
  • Established Fukushima Kasei Co., Ltd. (1967)
  • 1969 Fukushima Kasei name changed to Eiko Kasei Co., Ltd
  • Launched blood analyzers and reagents,
    entry into the clinical test drug instrument sector (1971)
  • Constructed the Fujieda Plant (Shizuoka Prefecture) (1971)
  • Constructed the Fuji-Gotemba Research Laboratory
    (Shizuoka Prefecture) (1987)
  • Acquired Gen-Probe Incorporated (United States) (1989)
  • Launched Epogin®, a recombinant human
    erythropoietin, in Japan (1990)
  • Constructed the Utsunomiya Plant
    (Tochigi Prefecture) (October 1990)
  • 1991 Launched Granocyte®
  • Converted the London office (opened March 1986) into Chugai Pharma Europe Ltd.,
    an overseas subsidiary (United Kingdom, now a consolidated subsidiary) (1994)
  • Established Chugai Biopharmaceuticals, Inc.
    (United States, now Chugai Pharma USA, LLC.,
    a consolidated subsidiary) (1995)
  • Established Chugai Diagnostics Science Co., Ltd. (Tokyo) (1997)
  • Established Chugai Pharma Marketing Ltd
    (United Kingdom, now a consolidated subsidiary) (1997)
  • Opened the Tsukuba Research Laboratory
    (Ibaraki Prefecture) (2001)
  • Established Chugai Pharma France S.A.S.
    (France, now a consolidated subsidiary) (2001)
  • 2002 Chugai and Nippon Roche merged
  • Spun-off Gen-Probe Incorporated (2002)
  • Transferred all the shares of Chugai
    Diagnostics Science Co., Ltd.
    to Fujirebio Inc. (2002)
  • Established Chugai USA, Inc.
    (United States, now a consolidated subsidiary) (2002)
  • Closed the Takada Research Laboratory and the Matsunaga Plant (2003)
  • Transferred the over-the-counter
    medicines business to Lion Corporation
    • Transferred the OTC business to Lion Corporation
    • Transferred the insecticide manufacturing business of Eiko Kasei Co., Ltd. to Lion Packaging Co., Ltd. (2004)
  • Closed the Tsukuba Research Laboratory (2005)
  • Launched Actemra®, the world's first treatment
    for Castleman's Disease, in Japan (2005)
  • Transferred the Kagamiishi Plant and all stocks of
    Tohoku Chugai Pharmaceutical Co., Ltd.
    to Nipro Corporation (2005)
  • 2006 Succeeded to the business of
    manufacturing pharmaceutical products
    • Chugai Pharma Manufacturing Co., Ltd. succeeded to the business of manufacturing pharmaceutical products conducted at Chugai's Ukima Plant, Fujieda Plant, Utsunomiya Plant and Kamakura Plant as the result of a company split (2006)
  • Launched Tarceva®, an anti-cancer agent, in Japan (December 2007)
  • Launched Copegus®, an antiviral agent (2007)
  • Launched Avastin®, an anti-cancer agent (2007)
  • RoActemra® approved in the EU for rheumatoid arthritis (2009)
  • Closed the Kamakura plant of
    Chugai Pharma Manufacturing Co., Ltd. (2010)
  • 1920
  • 1930
  • 1940
  • 1950
  • 1960
  • 1970
  • 1980
  • 1990
  • 2000
  • 2010